According to medical technology company Biotricity, a wearable electrocardiogram (ECG) system that can diagnose and remotely monitor cardiac patients has received FDA clearance and is on track for release within the next quarter.
The system, called Bioflux, includes a high-precision, single-unit mobile cardiac telemetry (MCT) device capable of real-time data transmission. Together with proprietary software, customizable reports and a 24/7 monitoring center, the system is designed to be a complete cardiac monitoring solution that leverages internet of things connectivity on 3G and 4G cellular networks and merges seamlessly with physicians’ existing platforms and workflows.
Bioflux utilizes artificial intelligence designed to improve detection quality and patient outcomes, while also driving down costs. It provides a sampling rate of up to 1,000 readings per second, and records ECG data for up to 30 days on a secure cloud storage system. For more information, contact Biotricity.